In childhood acute lymphoblastic leukemia (ALL), chromosomal abnormalities define specific cytogenetic subgroups with distinctive clinical features. Of greatest significance is their association with outcome; well-known examples include the good prognosis associated with the translocation, t(12;21)(p13;q22)/ETV6-RUNX1 fusion, and the poor outcome linked to the presence of the Philadelphia chromosome. 1 Such abnormalities are now routinely used in risk stratification for treatment, which has made a substantial contribution to the remarkably improved outcome of 90% event free survival (EFS) for childhood B-cell precursor ALL (BCP-ALL). Intrachromosomal amplification of chromosome 21 (iAMP21) is a more recently identified chromosomal abnormality in childhood BCP-ALL, which has strong prognostic associations. Study of the processes leading to the formation of the iAMP21 chromosome has elucidated novel mechanisms important in leukaemogenesis, at least in this subtype, but likely with wider implications.
Cytogenetic definition of iAMP21
iAMP21 was identified as a distinct cytogenetic subgroup of BCP-ALL in 2003, 2, 3 following reports of a number of sporadic cases. It was detected whilst routine screening for the presence of the ETV6-RUNX1 fusion by fluorescence in situ hybridization (FISH). In the absence of the fusion, approximately 2% of childhood BCP-ALL patients showed additional copies of signals specific for the RUNX1 gene. The signals were seen in tandem duplication along the length of a grossly abnormal chromosome 21 (the iAMP21 chromosome) in metaphase and clustered together in interphase 2 ( Figure 1 ). From cytogenetic analysis, the morphology of the abnormal chromosome 21 varied markedly between patients, likely the explanation why it had not been previously described. Rare cases have been seen in which iAMP21 occurs in association with other established chromosomal changes, including high hyperdiploidy, BCR-ABL1 or ETV6-RUNX1, [4] [5] [6] otherwise it has been confirmed to be a primary cytogenetic change, which remains constant in structure between diagnosis and relapse. 7 Similar abnormalities of chromosome 21 have been rarely reported in acute myeloid leukemia and myelodysplastic syndromes, usually in association with complex karyotypes. 8, 9 However, the chromosomal regions involved in such cases appear to be different.
The complexity and variability of the iAMP21 chromosome in BCP-ALL, comprising multiple regions of gain, amplification, inversion and deletion, were further highlighted by FISH and genomic analysis. 7, 10, 11 However, in spite of the differences in their genomic profiles, consistent characteristics exist among iAMP21 patients. These features include a common region of highest level amplification spanning 5.1Mb of chromosome 21 from 32.8 to 37.9Mb, within which the RUNX1 gene is located, combined with the lowest level copy number distal of this region to the telomere 7 ( Figure 1 ). These observations have confirmed
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Interpretation of cases with interphase cells only should be made with caution, as extra RUNX1 signals will also define additional copies of chromosome 21, which are characteristic of high hyperdiploid ALL. As a result of such concerns, more recently the distinctive genomic profile of chromosome 21 is being used to confirm the accuracy of iAMP21 diagnosis ( Figure   1 ).
Although RUNX1 has been highlighted by its location within the highly amplified region of the chromosome and its use as a marker to define iAMP21, there is no evidence as yet that it is the target gene of this abnormality. RUNX1 was found not to be differentially expressed among gene expression profiles of childhood ALL patients, when samples from iAMP21 patients were specifically compared to samples from BCP-ALL patients with additional copies or other rearrangements of chromosome 21 (high hyperdiploidy and ETV6-RUNX1 with additional copies of the derivative chromosome 21, respectively). 11 In addition, no mutations of RUNX1 coding exons and specifically those within the Runt domain (exons 3, 4 and 5) have been found. 7, 14, 15 With good reason, RUNX1 is a strong candidate to be a driver of the leukemic process in iAMP21 patients, but in the absence of evidence, other genes within the amplified region and or rearranged within the abnormal chromosome 21
have equal opportunity.
Patients with iAMP21 display a unique spectrum of secondary genetic abnormalities, likely contributing to disease progression, which may also be used for improved diagnosis.
These include gain of chromosomes X, 10 or 14, or monosomy 7/deletion of 7q, deletions of 11q, including the ATM and MLL genes, P2RY8-CRLF2, deletions of ETV6 and RB1. 4, 7, 16 As the Down syndrome critical region on chromosome 21 overlaps with the common region of amplification in iAMP21, coupled with the observation that Down syndrome ALL patients also have a high incidence of gain of chromosome X 17 and P2RY8-CRLF2, 18 it was speculated that iAMP21 ALL may be related to Down syndrome ALL. If this be so, then the relationship is difficult to discern as iAMP21 has been seen in only a single Down syndrome ALL patient to date. 4 However, other constitutional abnormalities of chromosome 21, in particular the Robertsonian translocation, rob(15;21)(q10;q10)c, are related to iAMP21.
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Mechanism of formation
The complex structure and variability of the iAMP21 chromosome was sufficiently intriguing to warrant detailed genomic study in an attempt to elucidate the mechanism behind its formation. Earlier it had been shown from extensive FISH mapping that the abnormal chromosome 21 arose through a breakage-fusion-bridge (BFB) mechanism, 10 supported by the observation of anaphase bridges involving chromosome 21 in some iAMP21 patients. 19 Array based studies in conjunction with FISH had indicated gross copy number changes and complex structural rearrangements. 7, 11 Further analyses pointed to clustered breakpoints within the PDE9A gene in a number of patients involved in complex events around microhomology-mediated end joining as preceding or initiating the BFB cycles. 20 These observations raised hope that breakpoints within PDE9A may have been linked to initiation of the leukemogenic process of iAMP21. However, no further evidence has emerged.
An important observation which illuminated the mechanism came from the fascinating discovery that individuals born with the rare constitutional Robertsonian translocation between chromosomes 15 and 21, rob(15;21)(q10;q10)c, have ~2700-fold increased risk of developing iAMP21 ALL compared to the general population. 21 This is a striking enrichment considering the rarity of this constitutional change. In total Robertsonian translocations are found in ~1 in 1,000 newborns, 22,23 but rob(15;21)c account for only 0.5-1% of them. The association is remarkably specific, as they appear not to be predisposed to other subtypes of ALL or hematological malignancies. Intriguingly this strong association with iAMP21 ALL was not seen among the other more frequently occurring Robertsonian translocations. Genomic, cytogenetic and transcriptional analysis, coupled with next generation sequencing and novel bioinformatics approaches were used to identify genomic rearrangements and reconstruct the common principles underlying the temporal evolution of iAMP21 ALL. In the rob(15;21)c cases, amplification was initiated by chromothripsis, a process whereby localized genomic regions are shattered and rearranged in a one-off catastrophic event, simultaneously involving both sister chromatids of the dicentric Robertsonian chromosome 21 ( Figure 2 ). This finding implied that this constitutional, structural abnormality was specifically predisposed to leukemia through a novel mechanism, namely a propensity to undergo chromothripsis, likely related to its dicentric nature. One striking common feature of the rob(15;21)c-associated iAMP21 chromosomes was the loss of the chromosome 15 centromere, likely as a result of chromothripsis, providing mitotic stability of the derivative chromosome.
Further, it was confirmed that iAMP21 in non-rob(15;21)c patients (sporadic-iAMP21) was typically initiated by BFB events, leading to the formation of a dicentric chromosome 21.
These chromosomes then become prone to chromothripsis or other rearrangements ( is the first in ALL, but also the first to show that genomic instability in the form of large-scale copy number changes and other rearrangements can be coordinated in an ordered and sequential fashion. The remaining question is: how is this coordinated process initiated?
Clinical features
iAMP21 patients comprise 2% of childhood BCP-ALL, with roughly equal numbers of males and females, indicating a higher proportion of females than in other ALL subtypes.
24,25
Patients are older, with a median age of 9 years (range 2-30 years). The upper age limit remained consistent even when adult ALL series were examined. Approximately 50% are classified as high risk based on age ≥ 10 years, although they generally have low white cell counts.
4
Outcome A significant finding was that patients with iAMP21 had a poor 5 year EFS rate when treated on standard therapy, compared to other BCP-ALL patients treated on the same protocols. [26] [27] [28] The relapse rate was not only high, with a threefold increase compared to other BCP-ALL patients, but the temporal pattern of relapse was unusual, appearing constant over time, indicating the occurrence of both early and late relapses. Although the overall survival (OS) rate of 71% was also significantly worse compared to other patients, the large difference between EFS and OS indicated that some patients were being salvaged by post-relapse therapy. Based on these retrospective findings, in UK it was elected to treat iAMP21 patients as very high-risk regardless of other risk factors. Thus on the successor trial, iAMP21 patients were prospectively identified, stratified as high-risk and treated on the most intensive treatment arm. This proved to be successful with highly statistically significant improvements in 5 year EFS (from 29% to 78%), relapse risk (reduced from 70% v 16%) and OS (from 67% v 89%). 24 Similar findings were seen in a pair of contemporary Children's Oncology Group (COG) trials. 25 When children with standard-risk ALL were treated less intensively by COG, those with iAMP21 had a significantly inferior outcome compared to those patients without iAMP21. In contrast, children with high-risk ALL were treated more intensively by COG and there was no significant difference in the outcome of those with/without iAMP21. Concurring data were obtained from a large study from the International Childhood ALL Working Group (Ponte di Legno group), in which iAMP21 patient data were collected from 18 different study groups. 4 The same improved response
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Studies on the impact of minimal residual disease (MRD) in these patients have produced conflicting results. The Berlin Frankfurt Munster (BFM) group found that iAMP21 patients who were MRD positive had an inferior outcome compared with MRD negative patients, 28 whereas the results from the recent COG study suggested that MRD was not of prognostic relevance in this subgroup. 25 However, the COG and UK studies concurred in their conclusions that iAMP21 patients should assigned to the high-risk group and be treated intensively irrespective of MRD. These modifications are now in clinical practice, whereas BFM have not made such changes due to their rare, low-risk MRD iAMP21 patients having only moderate relapse risk on current therapy. B. A typical sporadic-iAMP21 copy number profile of the chromosome 21 derived from paired end sequencing data. 21 Fluctuations above and below a copy number of 2 indicate gain and deletion, respectively. The profile covers the whole of chromosome 21 from centromere (left had side) to telomere (right hand side) and he chromosome positions are indicated in Mb. The deletion of the telomeric region indicates the breakpoint from which the breakage-fusion-bridge (BFB) cycle was initiated in this patient. The stepwise changes in copy number along chromosome 21 represent the typical profile generated from BFB cycles, with the most highly amplified region juxtaposed to the deleted telomeric region. There are a small number of rearrangements resulting from chromothripsis in this patient. The originally defined common region of amplification of 5.1Mb is indicated by the red bar and the consistently most highly amplified and overexpressed regions generated from a consensus copy number profile 21 are indicated by the green bars. These regions include genes important in hematological malignancies, some examples with their relative locations are shown in the red box. Figure 2 Models for the evolution of the iAMP21 chromosome.
A. The rob(15;21)c is a constitutional dicentric chromosome fusing the short arms of one copy each of chromosomes 15 and 21. Usually one centromere is inactive to allow ordered separation of chromatids in mitosis. The model depicts the hypothesis that the two centromeres become active and confound attachment of mitotic spindles to the sister kinetochores, such that each chromatid connects to spindles emanating from opposite poles (Step 1). During anaphase, this merotelic attachment would lead to lagging of both sister chromatids, rendering them jointly prone to chromothripsis (shattering and then repair) ( Step 2) leading to a grossly rearranged rob(15;21)cassociated iAMP21 (Step 3).
B. Sporadic-iAMP21 formation is initiated by telomere attrition or double strand breakage (DSB) (Step 1). Following replication the unprotected chromosome ends fuse (
Step 2) leading to the formation of anaphase bridges and mitotic chromosome 1 1 double stand breakage typical of breakage-fusion-bridge (BFB) cycles (Step 3). This process is often repeated (Step 4). Chromothripsis of the resultant dicentric chromosome is initiated (Step 5) in the same manner as described for the rob(15;21)c-associated iAMP21 (Step 2 in Figure 1A ). The final step (Step 6) is repair of the shattered chromosome leading to generation of a stable abnormal chromosome 21.
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